[1] A.N. Serafini, Therapy of metastatic bone pain, J. Nucl. Med., 42 (2001) 895-906.
[2] J.A. Campa, R. Rayne, The management of intractable bone pain: a clinician’s perspective, Semin. Nucl. Med., 22 (1992) 3-10.
[3] J.F. Eary, C. Collin, M. Stabin, C. Vernon, S. Petersdorf, M. Baker, S. Hartnett, S. Ferency, S.J. Addison, F. Appelbaum, Samarium-153-EDTMP biodistribution and dosimetry estimation, J. Nucl. Med., 34 (1993) 1031-1036.
[4] A. Holmes, [153Sm]-EDTMP: a potential therapy for bone cancer, Semin. Nucl. Med., 22 (1992) 41-45.
[5] R.O. Robinson, D.F. Preston, J.A. Spicer, K.G. Baxter, Radionuclide therapy of intractable bone pain: Emphasis on Strontium-89, Semin. Nucl. Med., 22 (1992) 28-32.
[6] H.R. Maxon, S.R. Thomas, V.S. Hertzberg, L.E. Schroder, E.E. Englaro, R. Samaratunga, H.I. Scher, J.S. Moulton, E.A. Deutsch, K.F. Deutsch, H.J. Schneider, C.C. Williams, G.J. Ehrhardt, Rhenium-186-hydroxy-ethylidenediphosphonate for the treatment of painful osseous metastases, Semin. Nucl. Med., 22 (1992) 33-40.
[7] W.A. Volkert, T.J. Hoffman, Therapeutic radiopharmaceuticals, Chem. Rev., 99 (1999) 2269-2292.
[8] A. Bahrami-Samani, M. Ghannadi-Maragheh, A.R. Jalilian, S. Shirvani-Arani, M. Meftahi, S. Moradkhani, Production, quality control and biological evaluation of 153Sm-EDTMP in wild-type rodents, Iran J. Nucl. Med., 17 (2009) 12-19.
[9] H. Yousefnia, S. Zolghadri, A.R. Jalilian, M. Tajik, M. Ghannadi-Maragheh, Preliminary dosimetric evaluation of 166Ho-TTHMP for human based on biodistribution data in rats, Appl Radiat Isot., 94 (2014) 260-265.
[10] S. Zolghadri, A.R. Jalilian, H. Yousefnia, A. Bahrami-Samani, Y. Fazaeli, M. Pouladi, M. Ghannadi-Maragheh, H. Afarideh, The synthesis, radiolabeling and first biological evaluation of a new 166Ho-complex for radiotherapy of bone metastases, Radiochimica Acta., 101(7) (2013) 445-452.
[11] A. Bahrami-Samani, R. Bagheri, A.R. Jalilian, S. Shirvani-Arani, M. Ghannadi-Maragheh, M. Shamsaee, Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications, Sci Pharm., 78(3) (2010) 423-433.
[12] A.S. Shinto, D. Shibu, K.K. Kamaleshwaran, T. Das, S. Chakraborty, S. Banerjee, P. Thirumalaisamy, P. Das, G. Veersekar, 177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases, J. Nucl. Med. Tech., 42 (2014) 55-61.
[13] A. Bahrami-Samani, A. Anvari, A.R. Jalilian, S. Shirvani-Arani, H. Yousefnia, M.R. Aghamiri, M. Ghannadi-Maragheh, Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials, Iran. J. Pharm. Res., 11(1) (2012) 137-144.
[14] J. Yuan, C. Liu, X. Liu, Y. Wang, D. Kuai, G. Zhang, J.J. Zaknun, Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study, Clin. Nucl. Med., 38(2) (2013) 88-92.
[15] N. Ayati, K. Aryana, A.R. Jalilian, T. Hoseinnejad, A. Bahrami Samani, Z. Ayati, F. Shariati, S.R. Zakavi, Treatment efficacy of 153Sm-EDTMP for painful bone metastasis, Asia. Oceania. J. Nucl. Med. Biol., 1 (2013) 27-31.
[16] M.S. Alavi, Clinical trial project: Lu-177- EDTMP for Bone Pain Palliation of Bone Metastasis in Breast Cancer [Project], Shiraz University of Medical Sciences, Nuclear Medicine Center, (2010).
[17] H. Ranjbar, A. Bahrami-Samani, D. Beiki, S. Shirvani-Arani, M. Ghannadi-Maragheh, Evaluation of 153Sm/177Lu-EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent, J. Radioanal. Nucl. Chem., (2014) 1-9.
[18] H.G. Hughes, W.H. Egdorf, F.C Gallmeier, J.S Hendricks, R.C Little, G.W. McKinney, R.E. Prael, T.L Roberts, E. Snow, L.S Waters, M.C White, MCNPX user’s manual, version 2.4.0. Report LA CP 02-408. Los Alamos, NM: Los Alamos National Laboratory, (2002).
[19] J.F. Briesmeister, MCNPTM–a general Monte Carlo Nparticle transport code: version 4C. Report LA-13709-M. Los Alamos, NM: Los Alamos National Laboratory, (2000).
[20] ICRU. Photon, electron, proton and neutron interaction data forbody tissues, ICRU Report 46, Bethesda, MD:ICRU;, (1992).